UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _____________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTIO ...

Core Viewpoint - InterCure Ltd. announces the resignation of Mr. Ehud Barak as Chairman of the Board, effective February 13, 2025, with Mr. Alexander Rabinovich succeeding him as Chairman [1][2] Group 1: Leadership Changes - Mr. Ehud Barak, marking his 83rd birthday, steps down after six years of service, pursuing personal endeavors [2] - Mr. Alexander Rabinovich, who has been CEO for the past five years, will take over as Chairman, having led the company to significant profitable growth and strategic partnerships [1][5] Group 2: Financial Developments - InterCure completed a financing round securing NIS 66 million (approximately $18.2 million) to support the recovery of the Nir Oz Facility, with potential proceeds increasing to NIS 107 million (approximately $29.8 million) if warrants are fully exercised [3] - Key shareholders, including the CEO and lead investors, participated in the financing, which also included a loan agreement from a leading Israeli bank [3] Group 3: Recovery and Growth Strategy - The company is executing a war recovery plan to restore the Nir Oz facility, re-launch products, and rebuild its pharmaceutical cannabis portfolio [4] - InterCure aims to complete rehabilitation of the Nir Oz facility and secure compensation for war-related damages, which is essential for returning to profitable growth [5] - The company is focused on expanding international operations in Germany, the UK, and Australia, leveraging its successful financing round to reinforce its market position [5][7]

The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. Funding also includes a loan from a major Israeli bank. Completing the post-war damage recovery processes will enable the company to return to profitable growth withou ...

InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates. The company reported revenues of 126 million NIS ($33.97 million), surpassing the estimated 121 million NIS. However, this is still below pre-October 2023 levels of 414 million NIS, mainly due to the ongoing disruption at its southern Israeli facility, which has been occupied by the IDF. The company invested heavily in restoring this ...

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues). Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure's 16th and 17th consecutive quarter of profitability2. Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensation from the Israeli author ...

onuma Inthapong/E+ via Getty Images Investing Thesis InterCure (NASDAQ:INCR), a leading pharmaceutical/medical cannabis company based in Israel, and a global leader outside North America, has been hit hard by the Hamas attack and the war that followed and so has its stock. Despite these facts, the company managed to sustain operations and present positive 2023 results; the stock price also started recovering after market overreaction. While having the support of the state of Issael during this diffieult sit ...

Exhibit 99.1 InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million NEW YORK & HERZLIYA, Israel, April 30, 2024- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial Highlights and Milestones Adjusted EBITDA means EBITDA for the cannabis sector adjusted for changes in the fair va ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _____________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTIO ...

Morsa Images InterCure Ltd. (NASDAQ:INCR) has surprisingly rallied sharply off the post October 7 lows despite not having access to a prime facility in Israel. The cannabis business likely deserves a better stock valuation, but the dust needs to settle in both the Israel cannabis market and the conflict with Hamas. My investment thesis remains Bullish on the cannabis stock, even after the double off the lows already. Source: Finviz Still Waiting No matter where in the globe, cannabis has constantly been hit ...

Exhibit 99.1 Second Quarter and First Half 2023 Key Financial Highlights Second Quarter and First Half 2023 Key Operating Highlights All amounts are expressed in New Israeli Shekels (NIS) or Canadian Dollar ($). InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY Achieved record revenues of NIS 209 million ($75 million) for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149 million) Adjusted EBITDA of NIS 30 million ($11 million) Generated NIS 35 million ...